(TGTX) TG Therapeutics - Ratings and Ratios
Briumvi, Ublituximab, Tg-1701, Tg-1801
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 73.2% |
| Value at Risk 5%th | 92.4% |
| Relative Tail Risk | -23.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -9.40 |
| CAGR/Max DD | 0.43 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.524 |
| Beta | 0.472 |
| Beta Downside | 0.281 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.91% |
| Mean DD | 33.84% |
| Median DD | 31.56% |
Description: TGTX TG Therapeutics January 09, 2026
TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical firm that develops and markets novel B-cell-targeted therapies, primarily for multiple sclerosis (MS) and other B-cell-mediated diseases. Its flagship product, BRIUMVI (ublituximab), is an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. The pipeline includes a next-generation IV formulation of ublituximab, an oral BTK inhibitor (TG-1701), and a bispecific CD47/CD19 antibody (TG-1801), supported by multiple licensing and collaboration agreements with partners such as LFB, GTC, Jiangsu Hengrui, and Checkpoint Therapeutics.
Key recent metrics: TG Therapeutics reported Q2-2024 revenue of approximately $45 million, driven largely by BRIUMVI sales, while its net loss widened to $120 million as it ramped up R&D spending on the BTK and bispecific programs. The company’s cash runway is estimated at 18 months, assuming current burn rates and no new financing. Sector-wide, the global MS therapeutics market is projected to grow at a CAGR of ~5% through 2029, and BTK inhibitors are gaining traction as a potential oral alternative to infused anti-CD20 antibodies, which could reshape competitive dynamics with incumbents like Roche’s Ocrevus.
For a deeper quantitative dive into TG Therapeutics’ valuation metrics, you may find the ValueRay platform’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (447.5m TTM) > 0 and > 6% of Revenue (6% = 31.9m TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA -2.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 83.28% (prev 169.6%; Δ -86.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -70.1m <= Net Income 447.5m (YES >=105%, WARN >=100%) |
| Net Debt (179.6m) to EBITDA (115.2m) ratio: 1.56 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.0m) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 85.33% (prev 88.25%; Δ -2.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.03% (prev 45.18%; Δ 20.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.22 (EBITDA TTM 115.2m / Interest Expense TTM 27.3m) >= 6 (WARN >= 3) |
Altman Z'' -2.50
| (A) 0.43 = (Total Current Assets 599.8m - Total Current Liabilities 156.8m) / Total Assets 1.03b |
| (B) -1.08 = Retained Earnings (Balance) -1.11b / Total Assets 1.03b |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) 0.14 = EBIT TTM 115.0m / Avg Total Assets 805.5m |
| (D) -2.64 = Book Value of Equity -1.10b / Total Liabilities 417.8m |
| Total Rating: -2.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.63
| 1. Piotroski 4.0pt |
| 2. FCF Yield -1.41% |
| 3. FCF Margin -13.21% |
| 4. Debt/Equity 0.42 |
| 5. Debt/Ebitda 1.56 |
| 6. ROIC - WACC (= 12.82)% |
| 7. RoE 133.2% |
| 8. Rev. Trend 80.37% |
| 9. EPS Trend 60.03% |
What is the price of TGTX shares?
Over the past week, the price has changed by +10.28%, over one month by +2.14%, over three months by -12.96% and over the past year by +2.38%.
Is TGTX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.9 | 46.7% |
| Analysts Target Price | 44.9 | 46.7% |
| ValueRay Target Price | 31.9 | 4.2% |
TGTX Fundamental Data Overview January 19, 2026
P/E Forward = 23.8663
P/S = 9.1245
P/B = 7.9926
Revenue TTM = 531.9m USD
EBIT TTM = 115.0m USD
EBITDA TTM = 115.2m USD
Long Term Debt = 245.3m USD (from longTermDebt, last quarter)
Short Term Debt = 1.89m USD (from shortTermDebt, last quarter)
Debt = 253.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 179.6m USD (from netDebt column, last quarter)
Enterprise Value = 4.98b USD (4.85b + Debt 253.7m - CCE 131.6m)
Interest Coverage Ratio = 4.22 (Ebit TTM 115.0m / Interest Expense TTM 27.3m)
EV/FCF = -70.83x (Enterprise Value 4.98b / FCF TTM -70.2m)
FCF Yield = -1.41% (FCF TTM -70.2m / Enterprise Value 4.98b)
FCF Margin = -13.21% (FCF TTM -70.2m / Revenue TTM 531.9m)
Net Margin = 84.13% (Net Income TTM 447.5m / Revenue TTM 531.9m)
Gross Margin = 85.33% ((Revenue TTM 531.9m - Cost of Revenue TTM 78.0m) / Revenue TTM)
Gross Margin QoQ = 82.59% (prev 86.58%)
Tobins Q-Ratio = 4.85 (Enterprise Value 4.98b / Total Assets 1.03b)
Interest Expense / Debt = 2.65% (Interest Expense 6.72m / Debt 253.7m)
Taxrate = 8.64% (2.21m / 25.6m)
NOPAT = 105.1m (EBIT 115.0m * (1 - 8.64%))
Current Ratio = 3.82 (Total Current Assets 599.8m / Total Current Liabilities 156.8m)
Debt / Equity = 0.42 (Debt 253.7m / totalStockholderEquity, last quarter 607.2m)
Debt / EBITDA = 1.56 (Net Debt 179.6m / EBITDA 115.2m)
Debt / FCF = -2.56 (negative FCF - burning cash) (Net Debt 179.6m / FCF TTM -70.2m)
Total Stockholder Equity = 335.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 55.55% (Net Income 447.5m / Total Assets 1.03b)
RoE = 133.2% (Net Income TTM 447.5m / Total Stockholder Equity 335.8m)
RoCE = 19.79% (EBIT 115.0m / Capital Employed (Equity 335.8m + L.T.Debt 245.3m))
RoIC = 20.22% (NOPAT 105.1m / Invested Capital 519.5m)
WACC = 7.40% (E(4.85b)/V(5.11b) * Re(7.66%) + D(253.7m)/V(5.11b) * Rd(2.65%) * (1-Tc(0.09)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 6.07%
Fair Price DCF = unknown (Cash Flow -70.2m)
EPS Correlation: 60.03 | EPS CAGR: 135.2% | SUE: -0.42 | # QB: 0
Revenue Correlation: 80.37 | Revenue CAGR: 210.1% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.33 | Chg30d=+0.003 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.78 | Chg30d=-0.168 | Revisions Net=-1 | Growth EPS=-40.8% | Growth Revenue=+44.1%
Additional Sources for TGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle